Genome-wide association studies (GWAS) have identified over 40 genetic loci associated with colorectal cancer (CRC) risk. The association of single nucleotide polymorphisms (SNPs) at these loci with CRC risk and survival has not been adequately evaluated in East Asians. GWAS-identified CRC risk variants were used to construct weighted genetic risk scores (GRSs). We evaluated these GRSs in association with CRC risk in 3,303 CRC cases and 3,553 controls using logistic regression models. Associations with overall and CRC-specific survival were assessed in 731 CRC patients using Cox regression models. The association between the GRSs (overall and Asian-specific) and CRC risk was approximately twofold (highest vs. lowest quintile), and the shape of the dose-response was linear (p trend 5 1.24 3 10 213 and 3.02 3 10 214 for overall GRS and Asian-specific GRS, respectively). The association of the GRS with CRC risk was stronger among those with a family history of CRC (p interaction 5 0.007). Asian-specific GRS using previously reported survival SNPs increased risk for mortality and the shape of the dose-response was linear for CRC-specific and all-cause mortality (p trend 5 0.01 and 0.006, respectively). Furthermore, the minor alleles of rs6983267 and rs1957636 were associated with worse CRC-specific and overall survival. We show that GRSs constructed using GWAS-identified common variants are strongly associated with CRC risk in Asians. We confirm previous findings for the possible association between some SNPs with survival, and provide evidence for two additional CRC risk variants that may be related to CRC survival.
Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer-related mortality worldwide, resulting in over 1.6 million new cases and 771,000 deaths each year. 1 Recently, genome-wide association studies (GWAS) have identified multiple single nucleotide polymorphisms (SNPs) at approximately 40 loci associated with CRC susceptibility. Of these, 18 loci were identified in previous studies conducted in the Asia CRC Consortium. 9, 11, 12, [17] [18] [19] 23 Many of the risk variants initially identified in GWAS conducted among European descendants have not yet been investigated in Asian populations. In addition, no study has investigated the association of all these known risk variants collectively with CRC risk in Asians. Moreover, only a few studies have investigated the association between GWAS-identified risk variants and CRC prognosis, and the findings from these studies were inconsistent. [26] [27] [28] [29] [30] [31] [32] [33] In the present study, we provided a summary of all CRC risk loci identified by GWAS and examined their associations with CRC risk and survival among an Asian population.
Study (SWHS) (N 5 489), the Shanghai Men's Health Study (SMHS) (N 5 239) and the Shanghai Cancer Registry (N 5 2,575). Cancer-free controls for the study (N 5 3,553) were randomly selected from the SWHS (N 5 956), the SMHS (N 5 692), and the Shanghai GWAS of breast cancer (N 5 1,905).
The cases from the population-based Shanghai Cancer Registry were recruited between January 2009 and February 2011. The SWHS and the SMHS are two on-going, populationbased, prospective cohort studies, conducted in Shanghai, China. Details of the study designs and baseline questionnaires were published previously. 34, 35 Briefly, permanent residents of the study communities in Shanghai were approached for the study by trained interviewers. At baseline recruitment, anthropometric measurements and information on sociodemographic characteristics, lifestyle factors, and medical history were collected through in-person interviews. The SWHS recruited 74,942 women from 1997 to 2000 (participation rate 92.7%), and the SMHS recruited 61,480 men from 2002 to 2006 (participation rate 74.0%). These two cohorts have been followed up through a combination of in-person surveys every 2 to 4 years and annual record linkage with the populationbased Shanghai Cancer Registry and the Shanghai Vital Statistics Registry to identify incident cancer cases and causespecific mortality. CRC diagnosis and staging were assessed according to World Health Organization classifications and TNM classifications from the 7th edition of the American Joint Committee on Cancer. For cancer cases, clinical information was obtained by reviewing medical records and pathological slides. Participants with known hereditary CRC (e.g., Lynch syndrome) were excluded from the case populations. All participants provided informed consent for genetic analysis, and all studies were approved by the relevant institutional review boards for human research. The present analysis was restricted to study participants who were diagnosed with incident invasive colorectal adenocarcinoma during the study follow-up period and after the date of blood or buccal collection for DNA testing. For survival analysis, inclusion was restricted to the 731 CRC patients from the SWHS and SMHS for whom survival outcome data were available. For the analysis of genetic variants with CRC risk, however, all cases from the SWHS, SMHS, and those recruited through Shanghai Cancer Registry were included, along with their controls.
Genotyping, quality control and genotype imputation
Genomic DNA was extracted from blood samples or buccal cells using conventional methods. The details of genotyping and quality control for samples from the SWHS and SMHS were reported previously. 9, 11, 17, 23 The samples from the Shanghai Cancer Registry were genotyped with Infinium OncoArray-500 K Bead Chip (Illumina, San Diego, CA) in accordance with the manufacturer's protocol. Samples were excluded if the call rate was <95%, heterozygosity was <5% or >40%, were from close relatives, or contained discrepant gender information between self-reported and genetically determined. SNPs that met any of the following criteria were excluded: call rate <95%, p values <10 27 in the HardyWeinberg equilibrium test among the controls, a call rate of <95%, or a poor genotyping cluster plot. All the samples meeting the quality-control criteria were imputed with the 1000 Genome Project Phase 3 data as reference using the program Minimac3 (University of Michigan, Ann Arbor, MI).
SNP selection
We compiled a list of all the loci reported to be associated with CRC risk at p < 5 3 10 28 through literature review, which identified 57 SNPs at 42 loci associated with CRC (Table 1) . SNPs were excluded for the following reasons: a minor allele frequency of 5% in our study population (N 5 8), a low imputation quality (R 2 < 0.8) (N 5 13), SNPs in high linkage disequilibrium (LD) with each other (N 5 4), or SNP on the X chromosome (N 5 1). We excluded the SNP on the X chromosome, given this SNP is located in the non-pseudoautosomal region of the X chromosome (X: 9,751,474, Table 1 ). If SNPs were in linkage disequilibrium (LD; r 2 0.4, based on the 1000 Genome Project Phase 3
Asian population), the SNP derived from the largest sample size was included. After these exclusions, 38 SNPs were retained for analysis (Supporting Information Table 1 ).
Statistical analysis
Using an additive genetic model, we calculated weighted genetic risk scores (GRSs) using the natural log-odds ratios (ORs or b) as the SNP-specific weight which was obtained from previous studies having the largest combined sample sizes and showing statistically significant associations (Supporting Information Table 1 ). Two GRSs were calculated as the sum of the product of the weight (i.e., b) and the number of risk alleles (i.e., dosage) for k SNPs included in the GRS (i.e., P k i51 b i 3dosage i ) per individual. The overall GRS was calculated as the sum of weighted risk alleles across all 38 SNPs. Asian-specific GRS was calculated based on 25 SNPs that were identified or replicated in Asian populations. The GRSs were categorized into quintiles (Q) using the following cut-points for the overall GRS: Q1 4.14, Q2: 4.15 to 4.45, Q3: 4.46 to 4.72, Q4: 4.73 to 5.02, Q5 5.03; and the following cut-points for the Asian-specific GRS: Q1 2.57, Q2: 2.58-2.79, Q3: 2.80 to 2.99, Q4: 3.00 to 3.21, Q5 3.22. Differences in sociodemographic characteristics and lifestyle risk factors between controls and cases were evaluated using a t-test for continuous variables or a v 2 test for categorical variables. ORs and 95% confidence intervals (95% CIs) of weighted GRSs for CRC risk were derived from logistic regression models adjusted for age at diagnosis, sex, study sets, and principal components for ancestry, which were estimated using GWAS data. Stratified analyses were performed to assess whether the associations differed by age at diagnosis (<60, 60 years), sex, BMI (<25.0, 25.0-29.9, or >30.0 kg/m 2 ), or family history of CRC.
For survival analysis, we calculated the time from CRC diagnosis to death from CRC or any cause, or December 31, 2013 (the end of the follow-up period), whichever came first. Hazard ratios (HRs) and 95% CIs for CRC-specific and allcause mortality were estimated using Cox proportional hazard models to evaluate the associations of CRC survival with weighted GRSs. All models were adjusted for age, sex, tumor location, and stage. In addition, we conducted analyses of the GRSs in relation to survival stratified by age at diagnosis, sex, BMI (<25.0, 25.0-29.9, or >30.0 kg/m 2 ), tumor location (colon/rectum), and stage at diagnosis. We also used Cox proportional hazard regression models to estimate HRs and 95% CIs for individual SNPs. Kaplan-Meier survival curves were used to visualize the differences in unadjusted survival curves, and the log-rank test was performed to test the differences between groups. The proportional hazard assumption 4 The association for the six SNPs reported by Schumacher et al. 7 was mainly driven by the meta-analysis in European populations and thus they were classified as "first reported in European population". 5 Reference serial number. Abbreviations: RAF, risk allele frequency.
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was evaluated by using the likelihood ratio test for the multiplicative interaction term between weighted GRS and time in nested models; no violation was observed. All analyses were performed using SAS, version 9.4 (SAS Institute, Inc., Cary, NC), and all tests of statistical significance were set at p < 0.05 for two-sided analyses.
Results
There are 57 SNPs at 42 genetic loci reported to date in association with CRC risk at genome-wide significance (p < 5 3 10 28 ) ( Table 1) . Of these, 18 loci were first reported in GWAS conducted in populations of East Asian ancestry or in pooled analyses of data from East-Asian descendants and data from other populations (Table 1) . 9, 11, 12, [17] [18] [19] 23 An additional six SNPs were replicated in Asian-ancestry populations. 9, 12, 17 We excluded 19 SNPs from this analysis because they have a minor allele frequency <0.05 in Asians, had a low imputation quality (R 2 < 0.8) in our study, had high LD with other nearby SNPs selected for the study, or was on the X chromosome. After these exclusions, 38 SNPs remain for the present study (Supporting Information Tables 1 and 2 ).
Association of genetic risk scores with CRC risk
Sociodemographic characteristics and lifestyle risk factors of controls and CRC cases are shown in Supporting Information Table 3 . Because of the study design, more female controls than male controls were included in the analysis. CRC cases were more likely to be overweight, to have more education and a family history of CRC than controls. Both overall GRS (based on 38 SNPs) and Asian-specific GRS (based on 25 SNPs) were statistically significantly associated with CRC risk after adjusting for age, sex, study, and principal components following a dose-response pattern (p for trend 5 1.24 3 10 213 and 3.02 310 214 for overall GRS and Asian-specific GRS, respectively; Table 2 ). The ORs (95% CIs) comparing the fifth to the first quintile were 2.00 (95% CI: 1.60-2.50) and 2.05 (95% CI: 1.65-2.56) for overall GRS and Asian-specific GRS, respectively. Because of similar results for the overall and Asian-specific GRSs, additional analyses were performed for Asian-specific GRS only. We additionally examined the association of the overall GRS and Asian-specific GRS with CRC risk after further adjusting for potential CRC risk factors including smoking, alcohol use, physical activity, and red meat intake. However, our results did not change appreciably after adjustment (data not shown). Stratified analyses showed a statistically significant interaction between the GRS and family history of CRC (p for interaction 5 0.007) with a stronger association of GRS with CRC risk among individuals with a family history of CRC (per quintile: OR 5 1.84, 95% CI 5 1.16-2.93) than those without a family history of CRC (per quintile: OR 5 1.17, 95% CI 5 1.11-1.23) (Fig. 1) . No apparent multiplicative interaction was observed for the association between the Asian-specific GRS and CRC risk when stratified by sex (p for interaction 5 0.12), age (<60 vs. 601; p for interaction 5 0.18), and across BMI categories (<25 kg/m 2 , 25-29, and >30; p for interaction 5 0.86).
Association of genetic risk score with survival
Demographic, clinical, and pathologic characteristics of the 731 patients included in the survival analysis are shown in Supporting Information Table 4 . The median age at diagnosis was 67 years (range 42-83 years); 241 (33%) patients were male; and 442 (60.5%) patients were diagnosed with colon cancer. The clinical stages were as follows: 147 patients at stage I (23.6%), 168 patients at stage II (27.0%), 228 patients at stage III (36.6%), and 80 patients at stage IV (12.8%). The majority of the patients received surgery (N 5 688, 94.1%) and/or chemotherapy (N 5 586, 80.2%). By December 31, 2013, a total of 359 deaths had been documented, of which 319 were attributed to CRC.
Multivariable-adjusted HRs and 95% CIs for CRC-specific and all-cause mortality by quintiles of Asian-specific GRS were shown in Table 3 . No significant association was found between Asian-specific GRS and CRC-specific or all-cause mortality in the multivariable Cox regression analyses (Table  3 ) or in the Kaplan-Meier survival analysis (data not shown). We also constructed an Asian-specific GRS utilizing SNPs that have previously shown to be associated with survival among Asians (i.e., rs1321311, rs6983267, rs4939827, rs10411210, rs961253) 29, 30, 32 and found a statistically significant linear trend with both CRC-specific and all-cause mortality (Table 3) . Similar associations were observed for overall GRS with both CRC-specific and all-cause mortality (data not shown).We also evaluated whether the association of Asian-specific GRS with CRC-specific mortality may differ across the strata of potential predictors of survival, including age at diagnosis, sex, BMI, tumor location and stage (Supporting Information Fig. 1 ). There was no evidence of significant effect modification by any of these variables (p for heterogeneity >0.05). Finally, similar to the CRC risk analysis, we also examined the association between the overall GRS and Asian-specific GRS with mortality after adjusting for potential CRC risk factors including smoking, alcohol use, physical activity, and red meat intake. However, results from these sensitivity analyses did not alter our conclusions (data not shown).
We also investigated whether any individual SNP may be associated with CRC survival and found two SNPs (rs6983267 near gene MYC and rs1957636 near gene BMP4) showing suggestive associations. In Kaplan-Meier curves showing survival probability according to the genotypes of rs6983267 and rs1957636, the minor alleles of both SNPs (GG for rs6983267; CC for rs1957636) were associated with higher risk of CRCspecific death (rs6983267: log-rank p 5 0.06; rs1957636: logrank p 5 0.04) and death due to any cause (rs6983267: logrank p 5 0.01; rs1957636: log-rank p 5 0.07) (Fig. 2) . Multivariate Cox regression analyses also showed that these two SNPs were associated with CRC survival (Table 4) . When we calculated a risk score limited to these two SNPs, we observed significantly poorer CRC-specific survival (HR 5 2.22, 95% CI 5 1.11-4.47) and overall survival (HR 5 2.05, 95% CI 5 1.03-4.07) for patients homozygous for the minor allele in both SNPs. There was a dose-response relationship between the number of minor alleles of these two SNPs and risk of death due to CRC (p for trend 5 0.01) or any cause (p for trend 5 0.003) ( Table 4) . None of the remaining 36 SNPs was significantly associated with survival.
Discussion
In this study, we found that combinations of GWASidentified risk variants for CRC, as measured by both overall GRS and Asian-specific GRS, were strongly associated with CRC risk following a dose-response pattern in a Chinese population. However, neither overall GRS nor Asian-specific GRS was associated with survival among CRC patients. Two SNPs, rs6983267 on chromosome 8q24.21 and rs1957636 on 14q22.2, were significantly associated with CRC survival, providing some evidence that certain genetic variants identified for CRC risk may also be related to CRC survival.
Since 2008, genetic variants at 42 loci have been found to be associated with the risk of CRC. Although the association of CRC risk with each of these genetic variants is weak, typically with an OR of 1.2 or lower, the GRS, an aggregate measure of the effect of multiple risk variants, showed a strong association with CRC risk. In both overall and Asian-specific GRS, individuals in the highest quintile of the weighted GRS had a twofold increased risk of CRC compared with those in the lowest quintile, providing evidence that the GRS might be useful, in combination with other predictors, to identify high-risk individuals for primary prevention and cancer screening. A family history of CRC is one of the most important risk factors for CRC, and in our study the association of CRC risk with the GRS was stronger among individuals with a family history of CRC than for those without a family history of CRC. It has been shown previously that GRS improved the prediction of CRC risk when family history of CRC was considered. 36, 37 Our results, along with those from these previous studies, provide support for using GRS to further classify CRC patients with a family history of CRC into different risk groups for personalized prevention of this common cancer.
Several studies have examined the relationship between GWAS-identified CRC risk variants and CRC survival, most of which were conducted among European descendants and focused on the evaluation of individual SNPs; their results were inconsistent. There were two null association reports. 27, 28 However, positive findings were also reported. For example, Phipps et al. found the minor allele in rs4939827 (SMAD7) was associated with reduced overall and CRC-specific survival. 29 Dai et al. reported five SNPs (rs961253, rs355527, rs4464148, rs6983267 and rs10505477) were associated with survival for patients with stage III disease. 30 Morris et al. reported that rs4444235 was significantly associated with survival in CRC patients. 31 Smith et al. evaluated the influence of 20 GWAS-identified CRC risk SNPs in 7,635 cases, and found that patients who were homozygous for the minor allele (AA genotype) of rs9929218 had a poorer overall survival rate. 33 To date, only two studies have been conducted among East Asians. The study of Xing et al. found an association between rs4779584 and a reduced risk of CRC mortality in 380 Chinese CRC patients. 26 Kang et al. reported that rs1321311 (CDKN1A) and rs10411210 (RHPN2) were associated with survival for Korean patients with surgically resected CRC. 32 In our study, we found that the GG genotype of rs6983267 and the CC genotype of rs1957636 were significantly associated with poorer survival outcomes. The SNP rs6983267 was first identified in GWAS as a CRC susceptibility loci mapping to 8q24.1 in European descendants, 14 and was later replicated in East Asians. 17 This SNP has previously been reported to be significantly associated with survival outcomes for CRC patients 30 in the same direction as observed in the present study. The G allele of rs6983267 confers an increased CRC risk through the mechanism of Wnt signaling by disrupting an enhancer element and interacting with the promoter of the MYC oncogene. 38 MYC is a well-known oncogene and is overexpressed in many tumors, including CRC. 39 It lies 116 kb telomeric to rs6983267, and some reports have shown that rs6983267 has a long-range physical interaction with MYC in CRC cell lines. 38, 40 The variant rs6983267 that is associated with increased risk of colorectal adenomas 14 could also be associated with increased risk of CRC recurrence and initiation. Thus, it is possible that SNPs in MYC involved in CRC risk could also be related to CRC pathological severity and prognosis.
SNP rs1957636 was reported to be associated with increased risk of colorectal adenoma 41 suggesting that this SNP might play a role in the initiation of CRC. We did not find any significant association of this SNP with CRC risk in our study. However, we observed a significant association of the C allele in rs1957636 with poorer survival after CRC diagnosis. One would expect that genetic factors involved in colorectal tumor progression but not initiation might be more strongly associated with risk of CRC mortality. The reasons for our findings are unclear. SNP rs1957636 is upstream of the transcriptional start site of BMP4 (136 kb upstream) and 150 kb downstream to CRC susceptibility SNP rs4444235; however, rs1957636 and rs4444235 are not in strong LD. 21 Members of the BMP signaling pathway have been shown to interact with transforming growth factor-b (TGF-b), 42 which behaves as a tumor suppressor by inhibiting cell proliferation in normal tissue but promotes metastasis by enhancing angiogenesis and extracellular matrix disruption in the tumor. 29 The interaction between BMP4 and TGF-b and the pleiotropic functions of the TGF-b pathway may explain the seemingly opposite association of rs1957636 with null association for CRC but poor survival after CRC diagnosis.
The primary limitation of our study is the small sample size in the survival analysis. The statistical power is limited in the detection of a weak association with individual SNPs, particularly in stratified analyses by cancer stages. The significant association observed in this study for SNPs rs6983267 and rs1957636 was no longer statistically significant after taking into consideration multiple comparisons. Therefore, these associations should be further evaluated in future studies. Furthermore, the GRS included 17 SNPs that were initially identified in relation to CRC risk in the Asia CRC Consortium that include samples from the two Shanghai studies used in this analysis. However, the two Shanghai studies only account for 23% of samples in the Asia consortium. Furthermore, the current analysis includes data from Shanghai that was not included in the Asia CRC Consortium study that identified these risk variants. The strength of the association across the three studies was similar for all quintiles and the estimates were not significantly different from one another (i.e., p for heterogeneity for Quintiles 2, 3, 4, 5, vs. Quintile 1 5 0.71, 0.92, 0.97, 0.53, respectively). Thus, a pooled analysis of the individual-level data was conducted and adjusted for each individual study in the models. It is also possible that the alleles utilized in this analysis that were identified among European Americans may not be the purported risk allele among Asians. Thus, in the future the GRS could be further refined to include newly identified Asianspecific risk alleles.
In conclusion, our study indicated that GRSs constructed from risk SNPs identified in previous GWAS were significantly associated with CRC risk following a dose-response pattern, but they were not associated with CRC survival. However, common germline variants in GWAS-identified loci near the MYC and BMP4 genes may be associated with CRC survival. Further studies to independently evaluate these associations are warranted.
